Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261968 | 0.93 | BACE1 (0.39) | BACE1BACE2CTSDMMESLC6A2 | |
| SCHEMBL31391114 | 0.93 | SLC6A2 (0.36) | BACE1BACE2MMESLC6A2 | |
| SCHEMBL30600995 | 0.91 | SLC15A2 (0.39) | BACE1BACE2CTSD | |
| SCHEMBL30645271 | 0.91 | PDCD1LG2 (0.38) | BACE1MMESLC6A2 | |
| SCHEMBL3080050 | 0.90 | MME (0.37) | MME | |
| SCHEMBL3080046 | 0.90 | MME (0.37) | MME | |
| SCHEMBL29370926 | 0.90 | BACE1 (0.42) | BACE1BACE2CTSD | |
| SCHEMBL29559148 | 0.90 | FNTA (0.40) | MME | |
| SCHEMBL31514360 | 0.89 | PDCD1LG2 (0.37) | BACE1BACE2MMESLC6A2 | |
| SCHEMBL30607941 | 0.88 | BACE1 (0.41) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12234300-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4501952-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | HAMP, VIP, HDGF | BACE1 1262/4885BACE2 1803/4885ENPEP 85/4885 |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885ENPEP 90/4885 |
| US-12234300-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885ENPEP 90/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885ENPEP 90/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885ENPEP 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.